{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:07:05Z","timestamp":1794550025461,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology Program","award":["2023A04J2327"],"award-info":[{"award-number":["2023A04J2327"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2500300-4"],"award-info":[{"award-number":["2021YFC2500300-4"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangdong Province","award":["2023B110007"],"award-info":[{"award-number":["2023B110007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is no established standard treatment for acute myeloid leukemia (AML) patients with FLT3 wild-type relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multi-kinase inhibitor sorafenib has been widely explored in the treatment of AML patients with FLT3 internal tandem duplication (FLT3-ITD) mutations. Some studies have revealed that the addition of sorafenib to standard chemotherapy could improve outcomes in newly diagnosed AML regardless of FLT3 status. However, the application of sorafenib in FLT3 wild-type AML patients experiencing relapse after allo-HSCT remains minimally investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively compared the effects of conventional treatment combined with or without sorafenib on the outcomes of these patients. The study mainly focused on the treatment response of salvage therapy and survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixty-two AML patients with FLT3 wild-type who relapsed after allo-HSCT were enrolled in this study, including 38 with sorafenib and 24 without sorafenib. Fifty patients received 68 doses of donor lymphocyte infusion (DLI). The rate of composite complete remission was 65.8% in the sorafenib group, compared with 29.2% in the non-sorafenib group (<jats:italic>P<\/jats:italic>\u2009=\u20090.005). With a median follow-up of 13.2 months (IQR, 3.2\u201343.5) after relapse, the 2-year overall survival (OS) was 47.4% (95%CI, 33.9%-66.2%) and 16.7% (6.8%-40.8%) in the sorafenib and non-sorafenib groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). The 2-year event-free survival (EFS) was 44.7% (31.4%-63.7%) and 16.7% (6.8%-40.8%) in the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.012). Multivariable analysis revealed that salvage therapy including sorafenib was the protective factor for longer OS and EFS (HR\u2009=\u20090.395, 95% CI: 0.209\u20130.746, <jats:italic>P<\/jats:italic>\u2009=\u20090.004; HR\u2009=\u20090.406, 95% CI: 0.218\u20130.754, <jats:italic>P<\/jats:italic>\u2009=\u20090.004). The incidences of acute graft-versus-host disease (GVHD) and chronic GVHD were similar between the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.806, <jats:italic>P<\/jats:italic>\u2009=\u20090.908).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our results suggest that salvage therapy including sorafenib and DLI is associated with improved outcomes for AML patients with FLT3 wild-type relapsing after allo-HSCT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40364-025-00816-9","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:53:58Z","timestamp":1755644038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"13","author":[{"given":"Zhonghui","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangkun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"24","key":"816_CR2","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang BI, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26(24):6475\u201382.","journal-title":"Clin Cancer Res"},{"key":"816_CR3","doi-asserted-by":"crossref","unstructured":"de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, et al. Proceedings from the National cancer institute\u2019s second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transpl. 2014;20(1):4\u201313.","DOI":"10.1016\/j.bbmt.2013.08.012"},{"issue":"16","key":"816_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, et al. Addition of Sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691\u201399.","journal-title":"Lancet Oncol"},{"issue":"9","key":"816_CR5","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/cncr.31295","volume":"124","author":"L Xuan","year":"2018","unstructured":"Xuan L, Wang Y, Huang F, Jiang E, Deng L, Wu B, et al. Effect of Sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer. 2018;124(9):1954\u201363.","journal-title":"Cancer"},{"issue":"8","key":"816_CR6","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","volume":"25","author":"L Xuan","year":"2019","unstructured":"Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, et al. Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25(8):1674\u201381.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"816_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682\u201396.","journal-title":"Leukemia"},{"issue":"26","key":"816_CR8","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-Internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"issue":"9","key":"816_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"8","key":"816_CR10","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic Haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600\u201311.","journal-title":"Lancet Haematol"},{"issue":"17","key":"816_CR11","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.1182\/bloodadvances.2023010392","volume":"7","author":"AB Halpern","year":"2023","unstructured":"Halpern AB, Rodr\u00edguez-Arbol\u00ed E, Othus M, Garcia KA, Percival MM, Cassaday RD, et al. Phase 1\/2 study of Sorafenib added to cladribine, high-dose cytarabine, G-CSF, and Mitoxantrone in untreated AML. Blood Adv. 2023;7(17):4950\u201361.","journal-title":"Blood Adv"},{"issue":"9","key":"816_CR12","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","volume":"35","author":"C R\u00f6llig","year":"2021","unstructured":"R\u00f6llig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35(9):2517\u201325.","journal-title":"Leukemia"},{"issue":"2","key":"816_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13738","volume":"295","author":"S Yu","year":"2024","unstructured":"Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, et al. Sorafenib plus triplet therapy with venetoclax, Azacitidine and Homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study. J Intern Med. 2024;295(2):216\u201328.","journal-title":"J Intern Med"},{"issue":"1","key":"816_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"816_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"key":"816_CR16","unstructured":"National Comprehensive Cancer Network. Acute Myeloid Leukemia (version 2). 2025; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf"},{"issue":"3","key":"816_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L, O\u2019Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282\u201391.","journal-title":"Nat Med"},{"issue":"4","key":"816_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/hep.30666","volume":"70","author":"C Hage","year":"2019","unstructured":"Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, P\u00f6schinger T, et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer Cell-Mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 2019;70(4):1280\u201397.","journal-title":"Hepatology"},{"key":"816_CR19","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825\u201328."},{"issue":"12","key":"816_CR20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"27","key":"816_CR21","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"11","key":"816_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/cncr.34182","volume":"128","author":"X Chen","year":"2022","unstructured":"Chen X, Huang J, Xu N, Fan Z, Nie D, Huang F, et al. A phase 2 study of Sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 2022;128(11):2138\u201347.","journal-title":"Cancer"},{"issue":"3","key":"816_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl. 2015;21(3):454\u201359.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"816_CR24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/leu.2013.7","volume":"27","author":"T Schroeder","year":"2013","unstructured":"Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229\u201335.","journal-title":"Leukemia"},{"issue":"2","key":"816_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.2002.20.2.405","volume":"20","author":"JE Levine","year":"2002","unstructured":"Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic Stem-Cell transplantation. J Clin Oncol. 2002;20(2):405\u201312.","journal-title":"J Clin Oncol"},{"issue":"31","key":"816_CR26","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25(31):4938\u201345.","journal-title":"J Clin Oncol"},{"issue":"12","key":"816_CR27","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","volume":"20","author":"YB Chen","year":"2014","unstructured":"Chen YB, Li S, Lane AA, Connolly C, Del RC, Valles B, et al. Phase I trial of maintenance Sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transpl. 2014;20(12):2042\u201348.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00816-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00816-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:16:54Z","timestamp":1757438214000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00816-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00816-9","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was first approved by Medical Ethics Committee of Nanfang Hospital of Southern Medical University. Subsequently, the remaining four centers conducted ethical filing. This trial was reviewed and approved by the ethics committee review board at each participating center and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}